Related references
Note: Only part of the references are listed.Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
Timothy J. Carrothers et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States
Keith S. Kaye et al.
CLINICAL INFECTIOUS DISEASES (2019)
Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections
Urania Rappo et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia
Todd A. Riccobene et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age
Daniel Gonzalez et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
Michael W. Dunne et al.
CLINICAL INFECTIOUS DISEASES (2016)
Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target
A. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
Steven Y. C. Tong et al.
CLINICAL MICROBIOLOGY REVIEWS (2015)
Dalbavancin for the treatment of acute bacterial skin and skin structure infections
Sheena Ramdeen et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI): PRACTICE GUIDELINES FOR MANAGEMENT AND CARE TRANSITIONS IN THE EMERGENCY DEPARTMENT AND HOSPITAL
Charles V. Pollack et al.
JOURNAL OF EMERGENCY MEDICINE (2015)
Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age
John S. Bradley et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2015)
Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
Jordan R. Smith et al.
INFECTIOUS DISEASES AND THERAPY (2015)
Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009
Jose A. Suaya et al.
BMC INFECTIOUS DISEASES (2014)
Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
Dennis L. Stevens et al.
CLINICAL INFECTIOUS DISEASES (2014)
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
Helen W. Boucher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical Management of Skin and Soft Tissue Infections in the U.S. Emergency Departments
Rakesh D. Mistry et al.
WESTERN JOURNAL OF EMERGENCY MEDICINE (2014)
Skin and Soft Tissue Infections
Rakesh D. Mistry
PEDIATRIC CLINICS OF NORTH AMERICA (2013)
Trends in Resource Utilization for Hospitalized Children With Skin and Soft Tissue Infections
Michelle A. Lopez et al.
PEDIATRICS (2013)
Increasing national burden of hospitalizations for skin and soft tissue infections in children
Timothy B. Lautz et al.
JOURNAL OF PEDIATRIC SURGERY (2011)
Emergency Department Treatment Failures for Skin Infections in the Era of Community-Acquired Methicillin-Resistant Staphylococcus aureus
Rakesh D. Mistry et al.
PEDIATRIC EMERGENCY CARE (2011)
New Intrauterine Growth Curves Based on United States Data
Irene E. Olsen et al.
PEDIATRICS (2010)
Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment
Thomas Marbury et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
New Equations to Estimate GFR in Children with CKD
George J. Schwartz et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Human renal function maturation: a quantitative description using weight and postmenstrual age
Malin M. Rhodin et al.
PEDIATRIC NEPHROLOGY (2009)
Practice guidelines for the diagnosis and management of skin and soft-tissue infections
DL Stevens et al.
CLINICAL INFECTIOUS DISEASES (2005)
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
LE Jauregui et al.
CLINICAL INFECTIOUS DISEASES (2005)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens
I Raad et al.
CLINICAL INFECTIOUS DISEASES (2005)
Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers
A Leighton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Perls-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2004)
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections
E Seltzer et al.
CLINICAL INFECTIOUS DISEASES (2003)
Share Paper
